Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
Authors
Keywords
Melanoma, AKT inhibitor, Dabrafenib, Combination therapy, Drug resistance
Journal
Molecular Cancer
Volume 13, Issue 1, Pages 83
Publisher
Springer Nature
Online
2014-04-16
DOI
10.1186/1476-4598-13-83
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
- (2013) N. Wagle et al. Cancer Discovery
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
- (2013) E. M. Van Allen et al. Cancer Discovery
- Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance
- (2012) Edita Aksamitiene et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
- (2012) T. Shimizu et al. CLINICAL CANCER RESEARCH
- Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition
- (2012) Kavitha Gowrishankar et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms
- (2012) Ludovica Ciuffreda et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRAFV600E Negatively Regulates the AKT Pathway in Melanoma Cell Lines
- (2012) Brenden Chen et al. PLoS One
- Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
- (2012) Maria R. Girotti et al. Cancer Discovery
- Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
- (2011) Inna V. Fedorenko et al. BIOCHEMICAL PHARMACOLOGY
- Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
- (2011) F. Su et al. CANCER RESEARCH
- Combinatorial Treatments That Overcome PDGFR -Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition
- (2011) H. Shi et al. CANCER RESEARCH
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
- (2011) Nikhil Wagle et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
- (2011) Franziska Niehr et al. Journal of Translational Medicine
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition
- (2011) W. Deng et al. Pigment Cell & Melanoma Research
- Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
- (2011) Mohammad Atefi et al. PLoS One
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf-Mutant Human Cutaneous Melanoma Cells
- (2010) Y. N. V. Gopal et al. CANCER RESEARCH
- Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
- (2010) Jonas N Søndergaard et al. Journal of Translational Medicine
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- MEK1 mutations confer resistance to MEK and B-RAF inhibition
- (2009) C. M. Emery et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Combined Inhibition of MAPK and mTOR Signaling Inhibits Growth, Induces Cell Death, and Abrogates Invasive Growth of Melanoma Cells
- (2008) Konstantinos G. Lasithiotakis et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- The PTEN–PI3K pathway: of feedbacks and cross-talks
- (2008) A Carracedo et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search